Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Sedana Medical. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Sedana Medical's earnings available for a low price, and how does
this compare to other companies in the same industry?
Sedana Medical's earnings are expected to grow significantly at over 20% yearly.
Sedana Medical's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Sedana Medical's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Christer Ahlberg serves as the President and Chief Executive Officer of Sedana Medical AB (publ). He serves as CEO of Sedana Medical AB (publ) since February 01, 2017. Mr. Ahlberg has more than 10 years of experience in leading positions in sales and marketing at e.g. AstraZeneca, Meda and Wyeth. He served as Chief Executive Officer at Eisai AB since 2005 until 2010. He has more than 10 years of experience in leading positions in sales and marketing at e.g. AstraZeneca, Meda and Wyeth. He served as the Chief Executive Officer at Unimedic Group since 2010 until 2016. He served as the Chief Executive Officer at Eisai AB from 2005 to 2010. He served as the Chief Executive Officer at Unimedic AB from 2010 to May 21, 2016 and served as its Senior Director of Corporate Development from May 17, 2016 to March 10, 2017. He serves as a Director of PharmaControl MQL AB.
Insufficient data for Christer to compare compensation growth.
Christer's remuneration is lower than average for companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The average tenure for the Sedana Medical management team is less than 2 years, this suggests a new team.
President & CEO
VP and Head of R&D and Quality
Chief Financial Officer
Chief Operating Officer
VP & Head of Sales
Head of Marketing Director
Chief Medical Officer
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The average tenure for the Sedana Medical board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Sedana Medical AB (publ), a medical technology company, develops, markets, and sells medical devices in Sweden. The company provides AnaConDa and AnaConDa-S, a disposable medical device that enables the administration of volatile anaesthetics; AnaConDa Syringe, a 50/60ml syringe; FlurAbsorb, a charcoal filter for removing halogenated hydrocarbon anaesthetic gases, such as isoflurane or sevoflurane; FlurAbsorb accessory kit comprising lines and connectors for connecting the filter to the ventilator and gas monitor; and FlurAbsorb mounts to hold the filter during scavenging of anaesthetic gas. It also offers isoflurane/sevoflurane and Sevorane QuikFil filling adaptors; gas sampling lines to prevent anaesthetic volatile agents from leaching through the wall of the tube; and Nafion lines to reduce the accumulation of condensate in the anaesthetic gas measuring line and the water trap of the gas monitor. The company was founded in 2005 and is headquartered in Danderyd, Sweden.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.